In a development that could redefine the legal landscape surrounding drug patents, a Federal Circuit panel has revived the challenges brought by Teva Pharmaceuticals USA Inc. and Viatris Inc. against a patent held by Johnson & Johnson on their schizophrenia drug Invega Sustenna. The decision came on Monday, indicating that the patent’s validity would be once again under scrutiny.
Previously, the companies’ challenge to the patent was rejected, with a lower court employing what the Federal Circuit panel referred to as an “erroneously rigid” analysis. The specifics of this erroneous approach remain unclear without a detailed judgment, but this decision might hint at a shifting attitude in the courts regarding the robustness required in patent validity analysis.
The new opportunity for Teva and Viatris to confront the J&J patent offers a potentially significant turn in the larger pharmaceutical industry’s ongoing battles over drug patents. The outcome of this case could have substantial consequences not only for this schizophrenia drug but potentially for other patents held by large pharmaceutical corporations.